Barbara Klencke - Net Worth and Insider Trading
Barbara Klencke Net Worth
The estimated net worth of Barbara Klencke is at least $1 Million dollars as of 2024-05-15. Barbara Klencke is the Chief Development Officer of Sierra Oncology Inc and owns about 15,000 shares of Sierra Oncology Inc (SRRA) stock worth over $824,850. Barbara Klencke is also the Director of TScan Therapeutics Inc and owns about 55,000 shares of TScan Therapeutics Inc (TCRX) stock worth over $494,450. Details can be seen in Barbara Klencke's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Barbara Klencke has not made any transactions after 2023-12-14 and currently still holds the listed stock(s).
Transaction Summary of Barbara Klencke
Barbara Klencke Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Barbara Klencke owns 4 companies in total, including Sierra Oncology Inc (SRRA) , eFFECTOR Therapeutics Inc (EFTR) , and TScan Therapeutics Inc (TCRX) among others .
Click here to see the complete history of Barbara Klencke’s form 4 insider trades.
Insider Ownership Summary of Barbara Klencke
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SRRA | Sierra Oncology Inc | 2020-08-18 | Chief Development Officer |
| EFTR | eFFECTOR Therapeutics Inc | 2021-11-01 | director |
| TCRX | TScan Therapeutics Inc | 2023-12-14 | director |
 | | 2023-09-15 | director |
Barbara Klencke Latest Holdings Summary
Barbara Klencke currently owns a total of 2 stocks. Among these stocks, Barbara Klencke owns 15,000 shares of Sierra Oncology Inc (SRRA) as of August 18, 2020, with a value of $824,850 and a weighting of 62.52%. Barbara Klencke also owns 55,000 shares of TScan Therapeutics Inc (TCRX) as of December 14, 2023, with a value of $494,450 and a weighting of 37.48%.
Latest Holdings of Barbara Klencke
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SRRA | Sierra Oncology Inc | 2020-08-18 | 15,000 | 54.99 | 824,850 |
| TCRX | TScan Therapeutics Inc | 2023-12-14 | 55,000 | 8.99 | 494,450 |
Holding Weightings of Barbara Klencke
Barbara Klencke Form 4 Trading Tracker
According to the SEC Form 4 filings, Barbara Klencke has made a total of 2 transactions in Sierra Oncology Inc (SRRA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Sierra Oncology Inc is the acquisition of 9,275 shares on August 18, 2020, which cost Barbara Klencke around $113,433.
According to the SEC Form 4 filings, Barbara Klencke has made a total of 1 transactions in TScan Therapeutics Inc (TCRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in TScan Therapeutics Inc is the acquisition of 5,000 shares on December 14, 2023, which cost Barbara Klencke around $25,400.
Insider Trading History of Barbara Klencke
- 1
Barbara Klencke Trading Performance
GuruFocus tracks the stock performance after each of Barbara Klencke's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barbara Klencke is 2.91%. GuruFocus also compares Barbara Klencke's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barbara Klencke within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Barbara Klencke's insider trading performs compared to the benchmark.
Performance of Barbara Klencke
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 3.2 | | | | | |
| Relative Return to S&P 500(%) | 1.74 | | | | | |
Barbara Klencke Ownership Network
Barbara Klencke Owned Company Details
What does Sierra Oncology Inc do?
Who are the key executives at Sierra Oncology Inc?
Barbara Klencke is the Chief Development Officer of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .
Sierra Oncology Inc (SRRA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Sierra Oncology Inc Insider Transactions
Barbara Klencke Mailing Address
Above is the net worth, insider trading, and ownership report for Barbara Klencke. You might contact Barbara Klencke via mailing address: C/o Sierra Oncology, Inc., 1820 Gateway Drive, Suite 110, San Mateo Ca 94404.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
